BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38474084)

  • 1. Integrated Bioinformatics Analysis Identified ASNS and DDIT3 as the Therapeutic Target in Castrate-Resistant Prostate Cancer.
    Jung AR; Shin S; Kim MY; Ha US; Hong SH; Lee JY; Kim SW; Chung YJ; Park YH
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
    Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
    Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
    Yan Y; Mao X; Zhang Q; Ye Y; Dai Y; Bao M; Zeng Y; Huang R; Mo Z
    Cancer Biomark; 2021; 31(1):87-96. PubMed ID: 33780364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.
    Sircar K; Huang H; Hu L; Cogdell D; Dhillon J; Tzelepi V; Efstathiou E; Koumakpayi IH; Saad F; Luo D; Bismar TA; Aparicio A; Troncoso P; Navone N; Zhang W
    Am J Pathol; 2012 Mar; 180(3):895-903. PubMed ID: 22245216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis.
    Wu YP; Ke ZB; Lin F; Wen YA; Chen S; Li XD; Chen SH; Sun XL; Huang JB; Zheng QS; Xue XY; Wei Y; Xu N
    Pathol Res Pract; 2020 Oct; 216(10):153109. PubMed ID: 32853947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods
    Wang JL; Wang Y; Ren GP
    J Zhejiang Univ Sci B; 2020 Mar.; 21(3):246-255. PubMed ID: 32133801
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
    Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
    Li Y; Shi H; Zhao Z; Xu M
    BMC Urol; 2022 Oct; 22(1):162. PubMed ID: 36258196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis.
    Liang X; Hu K; Li D; Wang Y; Liu M; Wang X; Zhu W; Wang X; Yang Z; Lu J
    DNA Cell Biol; 2020 May; 39(5):836-847. PubMed ID: 32101033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.
    Hagberg Thulin M; Jennbacken K; Damber JE; Welén K
    Clin Exp Metastasis; 2014 Mar; 31(3):269-83. PubMed ID: 24292404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
    Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
    Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
    Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
    Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.
    Huang J; Liu D; Li J; Xu J; Dong S; Zhang H
    Ann Med; 2023; 55(2):2260387. PubMed ID: 37729607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression.
    Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
    Cancer Genomics Proteomics; 2015; 12(6):391-6. PubMed ID: 26543085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.